Outcomes in patients with small node‐negative invasive breast cancer
暂无分享,去创建一个
A. Giuliano | F. Amersi | Xiao Zhang | J. Bao | Cory A. Donovan | A. Chung
[1] Jeong Eon Lee,et al. A risk stratification by hormonal receptors (ER, PgR) and HER-2 status in small (≤1 cm) invasive breast cancer: who might be possible candidates for adjuvant treatment? , 2010, Breast Cancer Research and Treatment.
[2] G. Hortobagyi,et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] M. Loda,et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a,bNOMO): clinicopathologic features and outcome. , 1997, Cancer.
[4] L. Habel,et al. Distant invasive breast cancer recurrence risk in human epidermal growth factor receptor 2-positive T1a and T1b node-negative localized breast cancer diagnosed from 2000 to 2006: a cohort from an integrated health care delivery system. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] C. Redmond,et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.
[6] T. Ignatov,et al. Management of small T1a/b breast cancer by tumor subtype , 2017, Senologie - Zeitschrift für Mammadiagnostik und -therapie.
[7] D. Noh,et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less , 2010, BMC Cancer.
[8] K. Bilimoria,et al. Treatment Trends and Factors Associated with Survival in T1aN0 and T1bN0 Breast Cancer Patients , 2007, Annals of Surgical Oncology.
[9] L. Livi,et al. Prognostic value of positive human epidermal growth factor receptor 2 status and negative hormone status in patients with T1a/T1b, lymph node‐negative breast cancer , 2012, Cancer.
[10] E. Winer,et al. Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] A. Vincent-Salomon,et al. Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] K. Boachie‐Adjei,et al. Effects of adjuvant chemotherapy in HER2-positive or triple-negative pT1ab breast cancers: a multi-institutional retrospective study , 2013, Breast Cancer Research and Treatment.
[13] P. Saigo,et al. Predictors of recurrence in stage I (T1N0M0) breast carcinoma. , 1981, Annals of surgery.
[14] R. Kreienberg,et al. Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients , 2016, Archives of Gynecology and Obstetrics.
[15] S. Chia,et al. Ten-year outcomes in a population-based cohort of node-negative, lymphatic, and vascular invasion-negative early breast cancers without adjuvant systemic therapies. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] W. Sikov,et al. Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: application and outcomes. , 2013, Breast.
[17] C. Hudis,et al. Favorable prognosis in patients with T1a/T1bN0 triple‐negative breast cancers treated with multimodality therapy , 2012, Cancer.
[18] N. Harbeck,et al. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry. , 2015, Breast.
[19] A. Goldhirsch,et al. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] N. Wolmark,et al. Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. , 2001, Journal of the National Cancer Institute.
[21] A. Luini,et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes , 2011, Breast Cancer Research and Treatment.
[22] F. Cardoso,et al. Small breast cancers: when and how to treat. , 2014, Cancer treatment reviews.
[23] Funda Meric-Bernstam,et al. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Z. Tong,et al. Clinical features and survival analysis of T1mic, a, bN0M0 breast cancer. , 2012, Japanese journal of clinical oncology.